Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Carreira, Suzanne; Porta, Nuria; Arce Gallego, Sara; Seed, George; Llop Guevara, Alba; Bianchini, Diletta; Serra Elizalde, Violeta; Mateo Valderrama, Joaquim

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Carreira, Suzanne
dc.contributor.author	Porta, Nuria
dc.contributor.author	Arce Gallego, Sara
dc.contributor.author	Seed, George
dc.contributor.author	Llop Guevara, Alba
dc.contributor.author	Bianchini, Diletta
dc.contributor.author	Serra Elizalde, Violeta
dc.contributor.author	Mateo Valderrama, Joaquim
dc.date.accessioned	2021-07-01T10:54:33Z
dc.date.available	2021-07-01T10:54:33Z
dc.date.issued	2021-05-27
dc.identifier.citation	Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, et al. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discov. 2021 May 27;candisc.0007.2021.
dc.identifier.issn	2159-8290
dc.identifier.uri	https://hdl.handle.net/11351/6114
dc.description	Pròstata; PARP; Biomarcadors
dc.description.sponsorship	TOPARP is an investigator-initiated trial; we are grateful for the support and funding from AstraZeneca, and for the study grants from Cancer Research UK (CRUK/11/029; C12540/A12829; C12540/A13230; C12540/A20447). ICR-CTSU also receives program grant funding from Cancer Research UK (Grant number: C1491/A15955, C1491/A25351). We acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002), the Prostate Cancer Foundation, and the UK Department of Health through an Experimental Cancer Medicine Centre (ECMC) grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Pasquale Rescigno was supported by a PCF Young Investigator Award 19YOUN19. The authors affiliated to VHIO acknowledge funding from “La Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 (LCF/TR/CC19/52470003), Fundacion FERO and Fundacion Cellex. J. Mateo, A. Llop-Guevara and V. Serra received grants from Fundacion Cientifica AECC (LABAE16020PORTT) and an ERAPERMED2019-215. J. Mateo gratefully acknowledges funding from the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant 837900), Instituto de Salud Carlos III (Grant PI18/01384), Fundación AECC, CRIS Cancer Foundation and the US Department of Defense CDMRP (Impact Award PC170510P1). S. Arce-Gallego Research. Downloaded from cancerdiscovery.aacrjournals.org on July 1, 2021. © 2021 American Association for Cancer Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 27, 2021; DOI: 10.1158/2159-8290.CD-21-0007 3 and V. Serra were supported by Instituto de Salud Carlos III (FI19/00280, CPII19/00033).
dc.language.iso	eng
dc.publisher	American Association for Cancer Research
dc.relation.ispartofseries	Cancer Discovery;
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Pròstata - Càncer - Tractament
dc.subject	ADN - Reparació
dc.subject	Medicaments antineoplàstics
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	/drug therapy
dc.subject.mesh	DNA Repair
dc.title	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1158/2159-8290.CD-21-0007
dc.subject.decs	neoplasias de la próstata
dc.subject.decs	/farmacoterapia
dc.subject.decs	reparación del ADN
dc.relation.publishversion	http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-21-0007
dc.type.version	info:eu-repo/semantics/acceptedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Carreira S, Porta N, Seed G] The Institute of Cancer Research, London, UK. [Arce-Gallego S, Llop-Guevara A, Serra V] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mateo J] The Institute of Cancer Research, London, UK. The Royal Marsden NHS Foundation Trust, London, UK. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid	34045297
dc.relation.projectid	info:eu-repo/grantAgreement/EC/H2020/837900
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01384
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2017-2020/FI19%2F00280
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2017-2020/CPII19%2F00033
dc.rights.accessrights	info:eu-repo/semantics/openAccess